Pioneering The Next Generation of Solid Tumor T Cell Immunotherapies Maverick Therapeutics, Inc. has been acquired by Takeda Pharmaceutical Company Limited. To learn more about the acquisition, visit Takeda’s website here. To continue to Maverick’s website, please dismiss this notice. Close Who We Are Focusing on improving the lives of patients with solid tumor cancers. Our Science Developing the most mature bispecific T cell engaging platform in its class. Pipeline Advancing our COBRA™ pipeline toward the clinic.